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http://dx.doi.org/10.1016/j.ccr.2013.08.003SUMMARYLysosomal membrane permeabilization and subsequent cell death may prove useful in cancer treatment,
provided that cancer cell lysosomes can be specifically targeted. Here, we identify acid sphingomyelinase
(ASM) inhibition as a selective means to destabilize cancer cell lysosomes. Lysosome-destabilizing experi-
mental anticancer agent siramesine inhibits ASM by interfering with the binding of ASM to its essential lyso-
somal cofactor, bis(monoacylglycero)phosphate. Like siramesine, several clinically relevant ASM inhibitors
trigger cancer-specific lysosomal cell death, reduce tumor growth in vivo, and revert multidrug resistance.
Their cancer selectivity is associated with transformation-associated reduction in ASM expression and sub-
sequent failure to maintain sphingomyelin hydrolysis during drug exposure. Taken together, these data iden-
tify ASM as an attractive target for cancer therapy.INTRODUCTION
Cancer cells frequently harbor genetic alterations that allow
them to escape spontaneous and therapy-induced apoptosis.
Resistance is often acquired already during an early phase of
tumor development when genetic changes cause defects in cas-
pase-dependent apoptosis pathways and provide transformed
cells with higher growth and survival potential (Hanahan and
Weinberg, 2011). Furthermore, cancers treated with chemother-
apeutic drugs often acquire the ability to efflux drugs bySignificance
Defective apoptosis signaling and multidrug resistance are p
sented here reveal acid sphingomyelinase (ASM) as a target f
is essential for lysosomal stability and survival of cancer cells, a
widely used cationic amphiphilic drugs, including tricyclic ant
inhibit ASM and trigger lysosomal cell death even in apoptosis-
prove efficacious in tumors with low sphingomyelinase activity
tumors that have acquired therapy resistance.
Caincreasing the expression of multidrug resistance (MDR) pro-
teins, P-glycoproteins of the ATP-binding cassette transporter
family (Gottesman et al., 2002). Thus, alternative cell death path-
ways capable of killing apoptosis- and therapy-resistant cancer
cells have gained vast interest among cancer researchers, lead-
ing to the identification of lysosomal cell death programs as
attractive means to circumvent therapy resistance (Cesen
et al., 2012; Groth-Pedersen and Ja¨a¨ttela¨, 2013).
The concept of lysosomal cell death was originally presented
by Christian de Duve, who was awarded the Nobel Prize inrime obstacles for successful cancer treatment. Data pre-
or the treatment of therapy-resistant cancers. ASM activity
s well as for multidrug-resistant phenotype. Of note, several
idepressants, antihistamines and calcium channel blockers,
and multidrug-resistant cancer cells. ASM inhibitors should
, or when combined with classic chemotherapy, even to treat
ncer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier Inc. 379
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Figure 1. Transformation Does Not Alter
Sensitivity to Detergents and Concanamy-
cin A or Uptake of Siramesine
(A and B) The NIH 3T3-vector (Vector) and
-c-srcY527F (Src) cells were left untreated (UT) or
treated as indicated for 26 hr. Cell death and
viability were determined by LDH release (A) and
MTT (B) assays, respectively. L-L, Leu-LeuOMe;
Sira, siramesine; ConA, concanamycin A.
(C) Endocytic capacity of cells was analyzed by
flow cytometry after treatment with 40 mg/mL
dextran-488 for 2 hr.
(D) Subcellular distribution of 3H-siramesine in
cells treated with 0.1 mM 3H-siramesine for 3 hr
followed by a 1 hr chase period. The radioactivity
in nuclei (Nucl), heavy membrane fractions (HMF),
light membrane fractions (LMF), and cytosol were
measured.
(E) The volume of the acidic compartment in
cells treated as indicated for 1 hr with 25 nM
LysotrackerRed present during the last 15minwas
measured by flow cytometry.
Error bars indicate SD from two independent
triplicate experiments in (B), three independent
triplicate experiments in (A), (C), and (E), or
a representative (n = 3) triplicate experiment
in (D).
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ASM as a Target for Cancer Therapy1974 for his discovery and characterization of lysosomes
as cellular ‘‘recycling bins.’’ Because of the potent hydrolytic
capacity of lysosomal enzymes, he also defined lysosomes as
‘‘suicide bags’’ that can cause cell and tissue autolysis upon
rupture (de Duve, 1983). This triggered an intensive search for
compounds that destabilize lysosomal membranes for the treat-
ment of cancer. As a result, amineswith long hydrophobic chains
and high pK values were identified as lysosomotropic detergents
with potential applications in cancer therapy (Firestone et al.,
1979). Interest in lysosomal cell death pathways waned, how-
ever, rapidly. This was largely due to the lack of proper assay
systems that could differentiate lysosomal rupture that causes
cell death from postmortal alterations in autolytic cells, as well
as the assumption that lysosomotropic detergents would be
equally toxic to normal and transformed cells (de Duve, 1983).
Accordingly, novel assays to study lysosomal membrane perme-
abilization, as well as realization that cancer cell lysosomes are
less stable than normal lysosomes, were needed to initiate a
new wave of interest in lysosomal cell death pathways in the
beginning of the 21st century (Fehrenbacher et al., 2004; Leist
and Ja¨a¨ttela¨, 2001). Subsequently, emerging genetic data have
corroborated the role of cathepsins as evolutionarily conserved
executors of cell death and the role of lysosomal leakage as a
significant mediator of both physiological (e.g., mammary involu-
tion) and pathological (e.g., degenerative and infectious dis-
eases) cell demise in diverse organisms from yeast, roundworm,
and fruit fly to mammals (Canbay et al., 2003; Guicciardi et al.,
2001; Halangk et al., 2000; Houseweart et al., 2003; Kinser and
Dolph, 2012; Kreuzaler et al., 2011; Luke et al., 2007; Matsuda
et al., 2012; Syntichaki et al., 2002).
We have recently identified siramesine (10-[4-[1-(4-fluoro-
phenyl)-1H-indol-3-yl]-1-butyl]spiro[iso- benzo furan-1(3H),40-
piperidine]) as a lysosomotropic detergent that kills transformed380 Cancer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier Inccells preferentially and shows potent antitumor activity in murine
xenograft models without detectable adverse effects (Ostenfeld
et al., 2005, 2008). Siramesine-induced nonapoptotic cell death
is associated with oxidative stress and leakage of lysosomal
proteases to the cytosol. The aim of this study was to reveal
themolecular basis of siramesine’s cancer-selective cytotoxicity
and, thereby, to identify new targets for the treatment of therapy-
resistant cancers.
RESULTS
Siramesine Inhibits Acid Sphingomyelinase Activity
Siramesine is a lysosomotropic detergent that shows cancer
specific cytotoxicity both in vitro and in vivo. In order to enlighten
the molecular basis underlying its cancer specificity, we
compared c-srcY527F- and vector-transduced NIH 3T3 murine
embryonic fibroblasts that are siramesine sensitive and resis-
tant, respectively (Ostenfeld et al., 2005). It is surprising that
c-srcY527F-driven malignant transformation failed to sensitize
NIH 3T3 cells to compounds that induce similar lysosomal
effects as siramesine, i.e., detergents that permeabilize lyso-
somal membranes (sphingosine and Leu-LeuOMe) and conca-
namycin A that neutralizes lysosomal pH (Figures 1A and 1B).
In spite of the enhanced endocytic capacity in transformed cells,
siramesine uptake and the subsequent neutralization of lyso-
somal pH were indistinguishable in c-srcY527F- and vector-trans-
duced cells (Figures 1C–1E). Thus, the cancer-selective toxicity
of siramesine must be due to its activities not previously associ-
ated with the cytotoxic potential of lysosomotropic detergents.
Siramesine is an amphiphilic amine that induces phospholipi-
dosis (Ostenfeld et al., 2008), a well-described ‘‘side effect’’ of
many clinically relevant and widely used cationic amphiphilic
drugs (CADs) (Halliwell, 1997). As basic substances, CADs.
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Figure 2. Siramesine Inhibits ASM Activity
(A–C) ASMactivities in lysates of NIH 3T3-vector and -c-srcY527F (A), Hkh2 andHCT116 (B), andMCF10A andMCF7 (C) cells that were treated as indicated for 1 hr.
(D) Quantitative PCR (qPCR) analysis of Smpd1mRNA levels in NIH 3T3-vector and -c-srcY527F cells treated as indicated for 1 hr. Hydroxymethylbilane synthase
(Hmbs1) served as an internal control. The expression is expressed relative to that in untreated NIH 3T3-vector cells.
(E) BIAcore analysis of the effect of indicated concentrations of siramesine and desipramine in 35% dimethyl sulfoxide (DMSO) on binding of prebound
recombinant ASM to BMP-containing liposomes at pH 4.5. Drug concentrations used here reflect the reported up-to-1,000-fold accumulation of CADs in
lysosomes (Anderson and Borlak, 2006).
(F) Quantitative lipid mass spectrometry analysis of lysosomes isolated from MCF7 cells treated as indicated. The monitored lipid species included ceramides
(Cer), hexocylceramides (HexCer), diosylceramides (Hex2Cer), sphingomyelins (SM), cholesterol (Chol), and phosphatidylcholines (PC). Error bars indicate SD for
a representative (n = 3) quadruplicate experiment in (A) through (C), duplicate experiment in (D) and (F), or triplicate experiment in (E).
*p < 0.05, **p < 0.01, and ***p < 0.001 as indicated or when comparing drug-treated samples to vehicle-treated ones in (E).
See also Figure S1.
Cancer Cell
ASM as a Target for Cancer Therapyaccumulate in acidic lysosomes where they inhibit the activity
of lipases, including acid sphingomyelinase (ASM) and acid
ceramidase, which are responsible for the lysosomal hydrolysis
of sphingomyelin to ceramide and ceramide to sphingosine,
respectively (Kornhuber et al., 2010). Prompted by our recent
data showing that ASM promotes lysosomal membrane integrity
(Kirkegaard et al., 2010), we asked whether the lysosome-per-
meabilizing effect of siramesine could be due to the inactivationCaof ASM. Supporting this hypothesis, siramesine reduced the
ASM activity in NIH 3T3-vector and NIH 3T3-c-srcY527F cells as
effectively as desipramine, a tricyclic antidepressant with a
well-documented ASM inhibitory capacity (Kolter and Sandhoff,
2010) (Figure 2A; Figure S1A available online). ASM inhibitory
effect of siramesine was observed in various human cell lines
(Figures 2B and 2C) and was not associated with changes in
Smpd1 messenger RNA (mRNA) levels (Figure 2D).ncer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier Inc. 381
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ASM as a Target for Cancer TherapyBis(monoacylglycero)phosphate (BMP) is an endolysosomal
phospholipid that serves as an essential docking lipid for ASM
and other sphingolipid-hydrolyzing enzymes by tethering them
to their substrates in BMP-rich intraluminal vesicles (Kolter and
Sandhoff, 2010). Desipramine and other CADs inhibit ASM
and, possibly, other sphingolipid-hydrolyzing enzymes by inter-
fering with the electrostatic attraction between the negatively
charged BMP and positively charged saposin domains found
in ASM itself and in cofactors of many lysosomal lipases (Kolter
and Sandhoff, 2010). BIAcore surface-plasmone resonance
analysis revealed that siramesine inhibited the binding of ASM
to BMP-containing liposomes even more effectively than desi-
pramine (Figure 2E). Contrary to desipramine, cytotoxic concen-
trations of siramesine did not markedly reduce cellular levels of
acid ceramidase, which, akin to ASM, is degraded by lysosomal
cathepsins following desipramine-induced release from BMP-
containing lysosomal membranes (Figure S1B).
To confirm that ASM was inhibited also in living cells, we used
quantitative lipid mass spectrometry. The rapid siramesine-
induced reduction in ASM activity in MCF7 cells (Figure 2C)
was followed by a significant lysosomal accumulation of major
sphingomyelin species and a corresponding decrease in cer-
amide levels (Figure 2F). A prolonged exposure to siramesine
resulted in a further accumulation of lysosomal sphingomyelin,
whereas lysosomal ceramide level returned to control levels
(Figure 2F). Also, at this later time point, lysosomal diosylcera-
mides accumulated significantly (Figure 2F). Notably, sirame-
sine-induced increase in sphingomyelin was more rapid and
greater in lysosomal membranes than in total cellular mem-
branes, whereas the late effects of siramesine on glycosylated
ceramides were more prominent in nonlysosomal membranes
(Figures 2F and S1C). Siramesine treatment induced a similar
sphingomyelin accumulation in NIH 3T3-c-srcY527F cells without
significant changes in ceramides or glycosylated ceramides
(Figure S1D).
Taken together, these data support the hypothesis that
the inhibition of the ASM activity inside the lysosomes is the
primary sphingolipid-modifying effect of siramesine. Sirame-
sine has two tertiary amine groups that can be protonated
at acidic pH and an estimated log P (hydrophobicity) value of
5.7 (ChemDraw software, CambridgeSoft). Based on these two
chemical facts and its ability to induce phospholipidosis,
interact with BMP, and inhibit ASM activity, siramesine can
be defined as a CAD and a functional inhibitor of ASM.Figure 3. CADs Display Cancer-Specific Cytotoxicity In Vitro and In Vi
(A) NIH 3T3-vector (Vector) and -c-srcY527F (Src) cells were treated with indicate
death was analyzed by the LDH release assay.
(B) Clonogenic survival of the same cells in (A) treated as indicated for 72 hr and
(C) Hkh2 and HCT116 cells were treated with CADs as indicated for 40 hr, and t
(D) Parental and highly invasive (.ip1) SKOV3 cells were treated with CADs as indic
desipramine; Nortript, nortryptyllin; Terfe, terfenadine;
(E) Vector- andBCL2-transducedMCF7 cells, parental (P) andMDRDu145 and PC
death was analyzed by the LDH release assay.
(F) Representative images of Alexa Fluor 488-dextran-loaded MCF7 cells treate
permeabilization (cytosolic Alexa Fluor 488-dextran staining) was obtained by cou
Scale bar, 20 mm.
Error bars indicate SD for a minimum of three independent triplicate experiment
*p < 0.05, **p < 0.01, and ***p < 0.001 when comparing similarly treated NIH 3T
SKOV3.ip1 in (D), MCF7-Vector and -Bcl-2 in (E), or treated and untreated cells
CaCADs Display Cancer-Specific Cytotoxicity In Vitro
Next, we asked whether clinically relevant CADs with reported
ASM inhibitory activity display cancer-specific cytotoxicity
similar to siramesine. Remarkably, micromolar concentrations
of CADs used for the treatment of depression (desipramine,
nortriptyline, and amitriptyline), malaria (chloroquine), allergies
(terfenadine), or hypertension (amlodipine) killed c-srcY527F-
transduced cells at concentrations that did not compromise
the survival of control cells (Figure 3A). The transformed cells
were also significantly more sensitive to the long-term cytotox-
icity of CADs as analyzed by the colony formation assay (Fig-
ure 3B). Similar c-srcY527F-induced sensitization to CADs was
observed in three independently transduced pairs of NIH 3T3-
vector and NIH 3T3-c-srcY527F cells (data not shown); sirame-
sine, desipramine, and amlodipine also killed K-Ras-driven
HCT116 colon carcinoma cells more effectively than their
K-Ras-depleted ‘‘detransformed’’ Hkh2 variants (Figure 3C).
Furthermore, all tested CADs, except for chloroquine, displayed
profound cytotoxicity against cancer cell lines of various origins,
including ovarian (SKOV3), breast (MCF7), prostate (PC3 and
Du145), cervix (HeLa), and bone (U-2-OS) cancers (Figures 3D
and 3E). CADs killed highly invasive SKOV3.ip1 variants of
SKOV3 cells (Yu et al., 1993), apoptosis-resistant Bcl-2-
transduced MCF7 cells (Høyer-Hansen et al., 2007), and multi-
drug-resistant PC3 and Du145 prostate cancer cells better or
as effectively as their parental counterparts (Figures 3D and 3E).
Similar to siramesine (Ostenfeld et al., 2005), other cytotoxic
CADs induced lysosomal membrane permeabilization in sensi-
tive target cells prior to the permeabilization of the plasma mem-
brane (Figure 3F; data not shown). The order of efficacy of the
tested drugs was the same in all cell lines tested, terfenadine
being the most potent with lethal dose 50 (LD50) values between
3 and 5 mM, followed by siramesine (LD50z 4–9 mM), amlopidine
(LD50z 20–40 mM), and nortriptylline (LD50z 20–60 mM). Desi-
pramine (LD50 z 40–70 mM) and chloroquine (LD50 > 100 mM)
had the weakest cytotoxic activity, correlating with their lesser
ability to inhibit ASM (Figure 2B).
CADs Display Cancer-Specific Cytotoxicity In Vivo
We have shown earlier that daily oral (p.o.) administration of sir-
amesine at 30 and 100 mg/kg inhibits the growth of orthotopic
MCF7 mammary cancer xenografts in immunodeficient mice
and WEHI-R murine fibrosarcoma allografts in immunocompe-
tent syngenic mice (Ostenfeld et al., 2005). Our attempts tovo
d concentrations of siramesine (Sira) or indicated CADs for 28 hr, and the cell
analyzed by counting the colonies 5 days later.
he cell death was analyzed by the LDH release assay.
ated for 44 hr, and the cell death was analyzed by the LDH release assay. Desi,
3 cells, HeLa, and U-2-OS cells were treated as indicated for 48 hr, and the cell
d as indicated for 20 hr. The percentage of cells with lysosomal membrane
nting ten randomly chosen areas, with aminimumof 50 cells for each condition.
s.
3-vector and -c-srcY527F in (A) and (B), Hkh2 and HCT116 in (C), SKOV3 and
in (F).
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Figure 4. CADs Display Cancer-Specific Cytotoxicity In Vivo
(A–E) MCF7 cells (103 106 cells in 100 ml PBS) were inoculated into an axillary mammary fat pad of estrone-treated female SCIDmice. After tumor manifestation,
the mice were treated p.o. with 200 ml vehicle (0.5% methylcellulose 15 in 0.9% NaCl solution) alone or with indicated doses of siramesine (in A–C), desipramine
(D), or terfenadine (E) at indicated intervals. Representative images of hematoxylin-eosin-stained tumors 4 days (C) or 6 weeks (D) after the first treatment are
(legend continued on next page)
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ASM as a Target for Cancer Therapyfind the minimal effective dose revealed that the anticancer
effect of siramesine was largely lost at 3 mg/kg/day, whereas
biweekly administration of 30 mg/kg was as effective as daily
treatment, and even a single dose of 100mg/kg inducedmassive
necrosis (an expected consequence of lysosomal cell death) in
tumors and attenuated their growth for several weeks (Figures
4A–4C). Notably, a biweekly treatment with 30 mg/kg desipra-
mine inhibited the growth of MCF7 xenografts as effectively as
the same dose of siramesine (Figure 4D). Even though desipra-
mine-treated tumors did not shrink, the histological analysis of
the remaining tumor masses 6 weeks after the start of the treat-
ment revealed large areas of fibrotic tissue suggestive of a
preceding therapy-induced necrosis corresponding to that
observed in siramesine-treated tumors 4 days after the treat-
ment (Figures 4C and 4D). The antihistamine terfenadine also
delayed the growth of MCF7 and SKOV3.ip1 xenografts at
biweekly doses of 10 and 30 mg/kg, respectively (Figures 4E
and 4F). Finally, we tested the efficacy of siramesine in an
aggressive RIP1-Tag2 transgenic model of pancreatic b-cell
cancer (Hanahan, 1985). As a consequence of simian virus large
T antigen expression in pancreatic b cells, RIP1-Tag2 mice
develop multiple islet tumors by 12–14 weeks of age. Daily treat-
ment with 100 mg/kg siramesine starting at the age of 11 weeks
significantly reduced the number of tumors in RIP1-Tag2 mice,
and the tumor burden was reduced by 40% (Figure 4G). Of
note, none of the treatment protocols induced weight loss or
other noticeable adverse effects, indicating that siramesine
and CADs display cancer specificity also in vivo.
Transformation Alters Sphingomyelin Metabolism
To enlighten themolecular basis of the cancer-selective cytotox-
icity of CADs, we investigated whether transformation altered
sphingomyelin metabolism. The data presented earlier already
revealed significant transformation-associated reduction in
ASM activity before and after CAD treatment (Figures 2A and
2B). The expression of ASM-encoding Smpd1/SMPD1, but not
that of acid ceramidase-encoding Asah1/ASAH1, was also
significantly reduced by transformation (Figures 5A and 5B). In
accordance with the reported lysosome-stabilizing effect of
ASM (Kirkegaard et al., 2010), the lysosomal membrane stability
was dramatically reduced in c-srcY527F-transformed cells with
low ASM activity, as measured by the leakage of acridine orange
from the lysosomes to the cytosol upon photo-oxidation
(Figure 5C).
In accordance with decreased sphingomyelin levels in tumor
tissues (colon, breast, esophagus, brain, and blood) and
transformed cells (Barcelo´-Coblijn et al., 2011; Hendrich and
Michalak, 2003), NIH 3T3-c-srcY527F and HCT116 cells had
significantly lower levels of sphingomyelin than their nontrans-shown. Note massive hemorrhagic necrosis in siramesine-treated tumors in (C) an
Error bars indicate SD for the indicated number of mice.
(F) SKOV3.ip1 cells (103 105 cells in 120 ml GelTrex) were inoculated into an axillar
were treated p.o. with 200 ml vehicle (0.5%methylcellulose 15 in 0.9%NaCl solutio
tumor diameter under 10 mm are plotted.
(G) The RIP-Tag2mice were treated p.o. with vehicle (n = 19) or 100 mg/kg/day s
14 weeks and the tumors were counted and measured. Geometric means are in
*p < 0.05, **p < 0.01, and ***p < 0.001 when comparing drug-treated mice to vehic
days 10 and 18, respectively. The p values in (D) refer to mice treated with the 3
Caformed control cells (Figures 5D and 5E). In search for the expla-
nation for the transformation-associated fall in sphingomyelin
levels, we sequenced the entire transcriptomes of three inde-
pendently transduced pairs of NIH 3T3-vector and -c-srcY527F
cells and analyzed the expression of genes related to sphingo-
myelin synthesis and hydrolysis. The data obtained confirmed
the significantly reduced expression of Smpd1 and revealed an
even stronger decrease in the expression of Smpd3 and Nsmaf,
which encode for neutral sphingomyelinase (NSM) 2 and NSM2
activation-associated factor, respectively (Figure 5F). Accord-
ingly, c-srcY527F-transduced cells had lower constitutive NSM
activity than control cells (Figure 5G). The expression of sphingo-
myelin synthases was either increased (Sgms2) or not affected
(Sgms1) (Figure 5F), and the levels of other genes encoding for
enzymes involved in sphingolipid metabolism also failed to
explain the transformation-associated reduction in sphingomye-
lin (Table S1). Instead, the decreased expression of Smpd1 and
Smpd3, as well as the increased expression of Sgms2, may be
compensatory consequences of the low sphingomyelin levels
in transformed cells. Of note, the transformation-associated
decrease in the expression of SMPD1 was not limited to the
model systems used here. An analysis of a published gene
expression microarray data set (Wolfer et al., 2010) revealed
ERBB2- and epidermal-growth-factor-induced decrease in
SMPD1 mRNA levels in MCF10A breast epithelial cells (Fig-
ure 5H), and a database search demonstrated a highly significant
cancer-associated reduction in SMPD1 expression in numerous
microarray studies comparing mRNA levels in tumors originating
from gastrointestinal tract, liver, head and neck, kidney,
pancreas, cervix, lung, brain, and lymphoid tissue with their
appropriate control tissues (Figure S2). Also SMPD3 mRNA
levels were significantly reduced in gastrointestinal and lung car-
cinomas as well as in diffuse large B cell lymphomas (Figure S2).
Transformation-Associated Changes in Sphingomyelin
Metabolism Sensitize Cells to Siramesine
Accumulation of sphingomyelin has a destabilizing effect on
lysosomes (Kirkegaard et al., 2010), and the maintenance of
low sphingomyelin levels may be especially important for cancer
cell lysosomes, whose membrane stability is compromised by
significantly increased proteolytic activity (Fehrenbacher et al.,
2008). Thus, the lower constitutive ASM and NSM2 activities,
as well as the lower residual ASM activity remaining after CAD
treatment, may provide a molecular explanation for the cancer
specific cytotoxicity of CADs. Fittingly, siramesine treatment
increased sphingomyelin levels in sensitive NIH 3T3-c-srcY527F
cells, while no increase was detected in resistant NIH 3T3-vector
cells (Figure 6A; Figure S1D). More important, pharmacological
inhibition of NSM sensitized nontransformed cells to siramesined large areas of fibrotic connective tissue in desipramine-treated tumors in (D).
y mammary fat pad of estrone-treated female SCIDmice. After 6 days, themice
n) alone or with 30mg/kg terfenadine twice a week. Percentages of mice with a
iramesine (n = 17) from week 11 of age. The mice were sacrificed at the age of
dicated by horizontal lines.
le-treated mice. In (B), p < 0.05 and p < 0.01 for all treated groups starting from
0 mg/kg siramesine. Scale bars, 100 mM.
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Figure 5. Transformation Alters Sphingolipid Metabolism and Destabilizes Lysosomes
(A and B) Smpd1/SMPD1 (ASM) and Asah1/ASAH1 (acid ceramidase) mRNA levels in NIH 3T3-vector (Vector) and -c-srcY527F (Src) cells (A) and in Hkh2 and
HCT116 cells (B) were determined by qPCR. The values are expressed relative to Ppia or PPIB (cyclophilin A or B) mRNA.
(C) Loss of lysosomal integrity was analyzed by live single-cell imaging of the increase in green fluorescence, which reflects the leakage of lysosomal acridine
orange to the cytosol (see Supplemental Experimental Procedures), after laser treatment in acridine orange-labeled NIH 3T3-vector and -c-srcY527F cells. Values
represent means for 13 movies recorded in three independent experiments performed with three independent pools of NIH 3T3-vector and -c-srcY527F cells.
(legend continued on next page)
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ASM as a Target for Cancer Therapy(Figure 6B), whereas ectopic expression of SMPD1, as well as
treatment with bacterial sphingomyelinase, protected trans-
formed cells (Figures 6C and 6D). Thus, nonlysosomal sphingo-
myelinases can protect cells against cytotoxicity induced by
ASM inhibitors. Furthermore, the sensitizing effect of 2-hydrox-
yoleic acid (2OHOA) (Figure 6E), a potent activator of sphingo-
myelin synthases (Barcelo´-Coblijn et al., 2011), suggested that
the siramesine-induced increase in cellular sphingomyelin
content is detrimental to cancer cells. The inability of ceramide,
sphingosine, and sphingosine-1-phosphate to rescue cells from
siramesine-induced cytotoxicity further endorsed the increase
in sphingomyelin, rather than the decrease in sphingomyelin
metabolites, as a mediator of lysosomal destabilization upon
ASM inhibition (Figure 6F). Accordingly, depletion of ASM, but
not that of acid ceramidase, sensitized cancer cell lysosomes
to photo-oxidation-induced destabilization (Figure 6G).
Heat Shock Protein 70 and a-Tocopherol Protect Cells
against CAD-Induced Cell Death
Transformation-associated destabilization of lysosomal mem-
branes can be counteracted by lysosomal heat shock protein
70 (Hsp70), which binds with high affinity to lysosomal BMP,
thereby stabilizing ASM-BMP interaction and enhancing ASM
activity (Kirkegaard et al., 2010). Concentrations of CADs that
effectively inhibited the binding of ASM to BMP-containing lipo-
somes failed to affect the Hsp70-BMP interaction (Figure 2E;
Figure 7A). Thus, we speculated that Hsp70 could protect
ASM-BMP interaction from the CAD-induced interference.
Accordingly, Hsp70-expressing immortalized embryonic fibro-
blasts and WEHI-S murine fibrosarcoma cells tolerated CADs
better than control cells (Figures 7B–7D). Further connecting
the ASM inhibitory activity of siramesine to its cytotoxic poten-
tial, a-tocopherol, which effectively inhibits siramesine-induced
cytotoxicity (Ostenfeld et al., 2005), completely prevented sira-
mesine-induced ASM inhibition (Figure 7E).
Inhibition of ASM Activity Reverts Multidrug-Resistant
Phenotype
Numerous studies have demonstrated the ability of CADs
to revert MDR, and already in 1995, Dr. Levade noticed that
CAD-mediated ASM inhibition correlated well with their ability
to revert MDR (Jaffre´zou et al., 1995). In order to challenge this
clinically attractive hypothesis, we created MDR variants of
PC3 and Du145 prostate carcinoma cells by a long-term expo-
sure to increasing concentrations of docetaxel. PC3-MDR (Fig-
ures S3A and S3B) and Du145-MDR (Ellegaard et al., 2013) cells
overexpressed MDR1-encoding ABCB1 gene and displayed(D and E) Lipid contents (mol%) of NIH 3T3-vector (Vector) and -c-srcY527F (Src)
spectrometry. All monitored lipid species are shown.
(F) Expression levels of indicated genes in three independent pairs of NIH 3T3-ve
sequencing (RNA-Seq).
(G) NSM activity in lysates of NIH 3T3-vector (Vector) and -c-srcY527F (Src) cells
(H) Expression of indicated genes (Affymetrix U133Plus2.0) in cells transduced w
medium supplemented with 2% horse serum for 26 hr (Wolfer et al., 2010). When in
2 hr before harvesting. a.u., arbitrary units.
Error bars indicate SD for a minimum of three independent duplicate experiments
(G), a representative (n = 3) duplicate experiment in (B), or three independently tr
comparing transformed or treated cells with control cells.
See also Figure S2and Table S1.
Casignificantly reduced sensitivity to microtubule-disturbing and
DNA-damaging drugs while remaining highly sensitive to all
tested CADs (Figure 3E). As expected, subtoxic concentrations
of siramesine and desipramine fully resensitized MDR cells to
docetaxel in vitro without affecting the level of MDR1 protein
(Figures 8A and S3C). Siramesine also resensitized PC3-MDR
xenograft tumors to docetaxel treatment in vivo (Figure 8B)
and reverted the MDR phenotype in human CEM/A7 T-lympho-
blasts in vitro (Figures S3D and S3E).
PC3-MDR and Du145-MDR cells had significantly higher
SMPD1 expression and slightly higher ASM activity than their
parental cells (Figures 8C and 8D), and they displayed other var-
iable signs of lysosomal activation (Figures S3B, S3F, and S3G).
In order to test whether the inhibition of ASM contributed to
the CAD-mediated reversal of MDR, we depleted the cells for
ASM by three nonoverlapping SMPD1 small interfering RNAs
(siRNAs). ASM depletion reverted the MDR phenotype as effec-
tively as that of MDR1, and ASM depletion alone was sufficient
to trigger significant cell death, especially in PC3-MDR cells, in
which the RNA interference was particularly efficient (Figures
8D and 8E).
DISCUSSION
The data presented above identify a subset of CADs as putative
anticancer agents and open a feasible, safe, and economically
sound possibility to test the clinical anticancer efficacy of antihis-
tamines, calcium channel blockers, tricyclic antidepressants,
and other widely used and relatively safe CADs with ASM inhib-
itory activity. In order to identify CADs with best anticancer effi-
cacy for clinical trials, it is of utmost importance to understand
the molecular basis of their cytotoxic mechanism and cancer
selectivity. Here, we provide several lines of evidence that sup-
port ASM inhibition as a key to cancer selective cytotoxicity of
CADs. Most convincing, ectopic expression of SMPD1, as well
as pretreatment of cells with purified sphingomyelinase, pro-
tected cancer cells against siramesine, whereas pharmacolog-
ical inhibition of NSM had a sensitizing effect. Moreover,
Hsp70, which stabilizes BMP-ASM interaction and enhances
ASM activity (Kirkegaard et al., 2010), conferred partial protec-
tion against siramesine- and desipramine-induced cytotoxicity,
and a-tocopherol-induced protection from siramesinewas asso-
ciated with the loss of siramesine’s ability to inhibit ASM. Finally,
the cytotoxic potential of CADs tested here correlated well with
their reported (Kornhuber et al., 2010) and measured ability to
inhibit ASM. This correlation was further endorsed by our prelim-
inary screen of clinically relevant CADs, which identified potentcells (D) and in Hkh2 and HCT116 cells (E) as analyzed by quantitative mass
ctor (Vector) and -c-srcY527F (Src) cells were analyzed by whole transcriptome
measured by an assay kit from Echelon.
ith an empty retrovirus (Vector) or pBabe encoding for ERBB2 and grown in
dicated cells transduced with empty vector were treated with 50 ng/ml EGF for
in (A) and (D) or triplicate experiments in (E), two quadruplicate experiments in
ansduced samples in (F) and (H). *p < 0.05, **p < 0.01, and ***p < 0.001, when
ncer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier Inc. 387
BA
0
10
20
30
40
50
Src SKOV3.ip1
DMSO
2OHOA
DMSO+Sira
2OHOA+Sira
**
***
LD
H
 re
le
as
e 
(%
 o
f t
ot
al
)
F
G
re
en
 fl
uo
re
sc
en
ce
 in
te
ns
ity
 
siRNA:
Laser exposure time (s)
SMPD1-2
ASAH1-1
ASAH1-2
Control
P = 5E-38
****
**
0.9
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
0 10 20 30 40 50 60 70 80 90
G
D
0
5
10
15
Vector Src
Untreated
Siramesine
S
ph
in
go
m
ye
lin
 
(m
ol
%
 o
f t
ot
al
 m
on
ito
re
d 
lip
id
)
**
0
10
20
30
40
50
60
70
80
LD
H
 re
le
as
e 
(%
 o
f t
ot
al
)
Sira (µM):
2.5   2.5    5    5    2.5   2.5    5    5    2.5   2.5   5     5    2.5   2.5   5     5  
6            6            6             6            6             6            6             6            6
Vector
Src 
 *
Src SKOV3.ip1
0
10
20
30
40
DMSO
SMase
Vehicle+Sira
SMase+Sira
 **
LD
H
 re
le
as
e 
(%
 o
f t
ot
al
)
EVehicle                     SMase
S
ira
m
es
in
e 
   
   
   
   
   
  D
M
S
O
Sphingosine (µM)     Sph-1-P (µM)       C16-Cer (µM)       C24-Cer (µM)
0
20
40
60
80
100
0
5
10
15
20
25
30
Vector
SMPD1*
M
TT
 re
du
ct
io
n 
(%
 o
f u
nt
re
at
ed
)
A
S
M
 a
ct
iv
ity
 
(p
m
ol
 H
M
U
 / 
µg
 p
ro
te
in
 / 
h)
***
***
***
***
C
Sira      Desi
2      4      35   µMDMSO
0
20
40
60
80
100
DMSO
GW4869
***
*
**
Sira (µM):   0     6      8     0      6     8
SrcVector
LD
H
 re
le
as
e 
(%
 o
f t
ot
al
)
*
Figure 6. Failure to Compensate for ASM Inhibition Leads to Accumulation of Sphingomyelin and Sensitization to Cell Death
(A) Relative sphingomyelin contents of NIH 3T3-vector (Vector) and -c-srcY527F (Src) cells left untreated or treated with 8 mM siramesine for 5 hr were analyzed by
mass spectrometry. Values are expressed as mol% of total monitored lipid (Cer, HexCer, Hex2Cer, SM, and PC).
(B) NIH 3T3-vector (Vector) and -c-srcY527F (Src) cells were pretreated with vehicle (DMSO) or 15 mM GW4869 for 1 hr before the treatment with indicated
concentrations of siramesine for 26 hr. Cell death was analyzed by the LDH release assay.
(C) Viability (MTT reduction, left) and ASM activity (right) of HeLa cells transfected with a plasmid encoding for SMPD1* or the corresponding empty vector 96 hr
earlier and treated as indicated for the last 48 hr.
(D) Cell death (LDH release) of NIH 3T3-c-srcY527F and SKOV3.ip1 cells treated with vehicle (DMSO) or 75 mMsphingomyelinase from Bacillus cereus (SMase) 72,
48, and 24 hr before 46 hr treatment with 6 mM (NIH 3T3-c-srcY527F) or 8 mM (SKOV3.ip1) siramesine, respectively. Representative images of NIH 3T3-c-srcY527F
cells are shown on right. Scale bar, 50 mm.
(E) NIH 3T3-c-srcY527F (Src) and SKOV3.ip1 cells were treatedwith vehicle (DMSO) or 400 mM2-hydroxyoleic acid (2OHOA) for 45 hr andwhen indicatedwith 6 mM
(Src) or 8 mM (SKOV3.ip1) siramesine for the last 28 hr. Cell death was analyzed by the LDH release assay.
(F) NIH 3T3-vector and -c-srcY527F cells were treated with indicated combinations of D-sphingosine (Sph), sphingosine-1-phposphate (Sph-1-P), C16-ceramide
(C16-Cer), C24-ceramide (C24-Cer) and siramesine (Sira) for 28 hr. Cell death was analyzed by the LDH release assay. The solvents used for Sph and C16-Cer
(DMSO), Sph-1-P (MeOH), or C24-Cer (EtOH/Dod) had no significant effect alone or with siramesine.
(G) Loss of lysosomal integrity was analyzed by live single-cell imaging of the increase in green fluorescence after laser treatment in acridine orange-labeled U-2-
OS cells pretreated for 72 hr with a nontargeting control siRNA or qPCR-validated siRNAs targeting SMPD1 (85% reduction in mRNA) or ASAH1 (82% and 85%
reduction in mRNA).
Error bars indicate SD for a minimum of three independent duplicate experiments in (A) or triplicate experiments in (B), (D), (E), and (F), one representative (n = 3)
quadruplicate experiment in (C), or four experiments with 20 movies each in (G).
*p < 0.05, **p < 0.01, and ***p < 0.001, as indicated or when comparing SMPD1 siRNA to control siRNA in (G).
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Figure 7. Hsp70 and a-Tocopherol Protect Cells against CAD-Induced Cell Death
(A) BIAcore measurement of the effect of indicated concentrations of siramesine and desipramine in 35% DMSO on binding of prebound rHsp70 to BMP-
containing liposomes at pH 4.5. Drugs were added 10 min after Hsp70 immobilization.
(B) Clonogenic survival of wild-type (WT) and Hspa1-transgenic (Hsp70) iMEFs treated as indicated for 24 hr was analyzed by counting colonies 7 days after the
treatment.
(C and D) Viability (MTT reduction) of wild-type (WT) and Hspa1-transgenic (Hsp70) iMEFs (C) and vector- and HSPA1-transduced (Hsp70) WEHI cells (D) treated
as indicated for 24 hr.
(E) NIH 3T3-vector (Vector) and NIH 3T3-c-srcY527F (Src) cells were left untreated or treated with 8 mMsiramesine for 24 hr before the analysis of the ASM activity
(left, cleavage of HMU-PC) or cytotoxicity (right, LDH release assay). When indicated, 200 mg/ml a-tocopherol or vehicle (EtOH) was added 1 hr before the drug.
Error bars indicate SD for a minimum of three independent experiments in (B), (C), (D), and (E) or a representative triplicate experiments out of three in (A).
*p < 0.05, **p < 0.01, ***p < 0.001, as indicated in (E) or when compared to vehicle-treated samples in (A), similarly treated iMEF-WT cells in (B) and (C), or WEHI-
Vector cells in (D).
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ASM as a Target for Cancer TherapyASM inhibitors with varying structures and medical uses (e.g.,
perhexilline, sertraline, clomiphene, astemizole, maproteline,
and tamoxifen) as effective inducers of cancer cell death,
whereas CADs with only marginal ASM inhibitory activity (e.g.,
diphenhydramine, haloperidol, mirtazapine, fexofenadine, and
mifepristone) were only weakly cytotoxic at concentrations up
to 100 mM (A.-M.E., unpublished data).
The cytoprotective role of ASM in cancer cells was corrobo-
rated by the ability of SMPD1 siRNAs to induce cell death in
PC3-MDR cells. The degree of cell death was, however, clearly
smaller than that induced byCADs, indicating that ASM inhibition
is not the sole cytotoxic mechanism of CADs. As discussed
earlier, CADs also induce the proteolysis of other lysosomal
lipases, including acid ceramidase (Kolter and Sandhoff, 2010),
which has been considered as a putative anticancer target due
to theproapoptotic effects of ceramide (Zeidan et al., 2008). Con-
trary to desipramine, which triggered a rapid degradation of acid
ceramidase in all tested cells, siramesine had either no effect or
increased acid ceramidase levels. Accordingly, lysosomes of sir-
amesine-treated cells accumulated sphingomyelin rather thanCaceramide prior to lysosomal leakage and cell death. Thus, ASM
inhibition and subsequent sphingomyelin accumulation are likely
to be the key changes in sphingolipid metabolism that underlie
the cytotoxic effect of CADs. This conclusion appears to be in
contrast to the reported ability of ASM to promote death-recep-
tor-induced or radiation-induced apoptosis in endothelial cells
(Jenkins et al., 2009). It should, however, be noted that the proap-
optotic function of ASM depends on the translocation of ASM to
the outer leaflet of plasma membrane, where ceramide-contain-
ing lipid microdomains enhance the activation of signaling mole-
cules involved in apoptotic signaling (Smith and Schuchman,
2008). Thus, ASM may have opposing effects on cell survival,
depending on its localization to either lysosomal or plasmamem-
branes. Optimally, the inhibition of ASM might inhibit therapy-
induced apoptosis in apoptosis-competent normal cells and
sensitize apoptosis-defective cancer cells to a nonapoptotic
lysosomal cell death pathway. The direct detergent activity of
CADs, as well as their ability to enhance the production of
reactive oxygen species, may be among the additional cyto-
toxic mechanisms that, together with ASM inhibition, lead toncer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier Inc. 389
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Figure 8. Inhibition of ASM Reverts Multidrug Resistance
(A) Apoptotic phenotype of parental (P) and MDR PC3 prostate carcinoma cells treated as indicated for 48 hr was determined by counting Hoechst-stained cells
with condensed nuclei. Over 100 randomly chosen cells were counted for each condition.
(B) PC3-MDR cells (5 3 106 in 100 ml PBS) were inoculated subcutaneously into the flank of male SCID mice. After tumor manifestation (day 3), the mice were
treated p.o. with 200 ml vehicle (0.5%methylcellulose 15 in 0.9%NaCl solution) alone or with siramesine (30 mg/kg). A weekly intraperitoneal treatment with 0.9%
NaCl with or without docetaxel (15 mg/kg) was initiated on day 7. Each treatment group contained five mice. One vehicle-treated mouse and one docetaxel-
treated mouse were sacrificed at days 29 and 10, respectively. The effect of neither drug alone was significant. Similar results were obtained in an independent
experiment in which treatment was initiated when tumor diameter reached 5 mm (data not shown). The asterisks and p values refer to comparisons of
combination treatment with vehicle and docetaxel, respectively.
(C) ASM activity in indicated cell lysates was determined by measuring the cleavage of HMU-PC.
(D) SMPD1 mRNA levels relative to ACTB mRNA were analyzed by qPCR 72 hr after transfection with indicated siRNAs.
(E) Cells transfected with the indicated siRNAs were 24 hr later left untreated or treated with 20 nM docetaxel for 48 hr. Apoptotic cell death (left) was analyzed as
in (A). The efficacy of SMPD1 siRNAs is demonstrated in (D) and that of ABCB1 siRNA is demonstrated in a representative immunoblot (right).
Error bars indicate SD for a minimum of three independent experiments—(A), (C), and (E),—a representative triplicate experiment (D), or 4 to 5 mice (B). *p < 0.05,
**p < 0.01, and ***p < 0.001 when compared as indicated, or with similarly treated control siRNA-transfected cells in (C).
See also Figure S3.
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ASM as a Target for Cancer Therapylysosomal permeabilization. Supporting the role of reactive oxy-
gen species in this process, depletion of ASM but not of acid
ceramidase, sensitized cancer cell lysosomes to photo-oxida-
tion-induced permeabilization.390 Cancer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier IncCancer selectivity and minimal toxicity are highly desired but
rarely achieved properties of anticancer agents. In this respect,
it is encouraging that siramesine and other tested CADs
displayed selective cytotoxicity toward transformed cells and.
Cancer Cell
ASM as a Target for Cancer Therapyshowed no detectable adverse effects in mouse models. More-
over, long-term use of CADs by millions of people has proven
them to be relatively safe, especially when compared with exist-
ing chemotherapeutics. Phase 1 studies of siramesine have also
proven it safe at doses that result in plasma concentrations
around 0.5 mM (single dose of 320 mg or 80 mg/day for
14 days p.o.; C. Volbracht, H. Lundbeck A/S, Valby, Denmark,
personal communication). Our data suggest that the cancer
selectivity of CADs is at least partially due to the significantly
altered sphingolipid metabolism in transformed cells. As a result,
transformed cells have lower residual ASM activity after CAD
treatment and accumulate sphingomyelin, whose increased
levels have been reported to be selectively toxic to transformed
cells (Barcelo´-Coblijn et al., 2011). An increase in the sphingo-
myelin/ceramide ratio modifies the steric conformation of
lysosomal membranes and hinders their fusion with other intra-
cellular vesicles and plasma membrane (Utermo¨hlen et al.,
2008). Thus, the additional changes in the lysosomal membrane
composition and volume as a result of the sphingomyelin-
induced reduction in lysosomal fusion capacity may contribute
to the CAD-induced destabilization of lysosomal membranes.
Because of its ability to inhibit autophagy, chloroquine is
currently tested as an anticancer agent in several clinical trials.
Thus, it should be noted that siramesine and clomipramine are
also effective inhibitors of autophagic flux (Ostenfeld et al.,
2008; Rossi et al., 2009), and based on their basic nature, all clin-
ically relevant CADs are likely to neutralize the lysosomal pH
effectively and thereby inhibit autophagic degradation. Because
the tumor environment is frequently characterized by low
nutrient and oxygen content, the clinical efficacy of CADs may
be further improved by their ability to prevent cytoprotective
autophagy in metabolically stressed cancer cells.
Taken together, our data introduce ASM as an utmost attrac-
tive target for the treatment of therapy-resistant cancers and
encourage extensive preclinical testing and subsequent clinical
cancer trials for siramesine and clinically well-characterized
and relatively safe CADs.
EXPERIMENTAL PROCEDURES
Cell Lines and Treatments
All cell lines are described in the Supplemental Experimental Procedures.
Siramesine was kindly provided by C. Volbracht (H. Lundbeck A/S), C16-cer-
amide (N-palmitoyl-D-erythro-sphingosine) and C24 ceramide (N-lignoceroyl-
D-erythro-sphingosine) were from Avanti Polar Lipids, and GW4869 was from
Cayman Chemical. Other chemicals were from Sigma-Aldrich, if not otherwise
stated.
Cell Survival and Lysosomal Stability
The cell density was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) reduction assay and the cell death was as-
sessed by lactate dehydrogenase (LDH) release assay (Roche), as described
previously (Foghsgaard et al., 2001). Cells with condensed chromatin were
determined using an OLYMPUS IX microscope with the UV channel by
counting condensed nuclei in cells stained with Hoeschst 33342 for
10 min. In order to assess clonogenic survival, the cells were seeded in
six-well plates at a low density (1,000–3,000 cells per well) and treated as
indicated. Five to 7 days after the treatment, the cells were washed with
PBS and incubated with crystal violet/methanol for 15 min, washed twice
in water, and dried. Colonies were counted manually. In all assays, great
care was taken to ensure equal density of the cell lines to be compared
when the drugs were added.CaLysosomal stability upon photo-oxidation was analyzed essentially as
described previously (Kirkegaard et al., 2010) and in the Supplemental Exper-
imental Procedures.
In order to visualize lysosomal membrane permeabilization, cells were
loaded with 200 mg/ml Alexa Fluor 488-dextran (10 kDa) and chased for 1 hr
in fresh medium before the indicated treatments. Pictures were taken with a
Zeiss Axiovert 200M fluorescence time-lapse microscope equipped with a
Colibri LED light source at 37C.
Enzyme Activity Assays
Cellular ASM and NSM activities were measured by the cleavage of HMU-PC
and by the Neutral Sphingomyelinase Assay Service kit from Echelon (T-1800),
respectively, as described in the Supplemental Experimental Procedures.
BIAcore
Large unilamellar vesicles (10 mol% sphingomyelin, 50 mol% phosphatidyl-
choline, 20 mol% cholesterol, and 20 mol% BMP) were prepared, and surface
plasmon resonance measurements using a BIAcore 3000 system were per-
formed essentially as described elsewhere (Kirkegaard et al., 2010) and in
the Supplemental Experimental Procedures. Recombinant proteins (1 mM,
60 ml in running buffer) were injected directly on the liposome surface. Recom-
binant ASM was kindly provided by K. Sandhoff (University of Bonn, Bonn,
Germany), and rHsp70 was generated using the pET-16b vector system
and Ni21-affinity-purification (Novagen).
Lipid Mass Spectrometry
Sample aliquots corresponding to 2 3 105 cells or lysosomes from 3 3 106
cells (purified by Fe2+-dextran fractionation as described in the Supplemental
Experimental Procedures) per 200 ml were spiked with 10 ml internal standard
mixture containing 85 pmol phosphatidylcholine 18:3/18:3, 60 pmol sphingo-
myelin 18:1;2/17:0;0, 45 pmol ceramide 18:1;2/17:0;0, 65 pmol galactosyl-
ceramide 18:1;2/12:0;0 and 65 pmol lactosylceramide 18:1;2/12:0;0. The
samples were subsequently extracted with 990 ml chloroform/methanol
(10:1, v/v) for 90 min as described elsewhere (Sampaio et al., 2011). The
lower organic phase was collected and evaporated. The lipid extract was dis-
solved in 100 ml chloroform/methanol (1:2, v/v). Lipid extracts were analyzed
in positive ion mode on a QSTAR Pulsar-i instrument (AB Sciex) equipped
with a TriVersa NanoMate (Advion Biosciences) as described elsewhere
(Ejsing et al., 2006; Zech et al., 2009) and in the Supplemental Experimental
Procedures. The lipid species were identified and quantified using LipidView
software (AB Sciex).
Tumor Xenografts
All animal studies were approved by Dyreforsøgstilsynet (Denmark) or the Uni-
versity of California, San Francisco, Institutional Animal Care andUseCommit-
tee (USA) and carried out in accordance with the National Institutes of Health
guidelines. MCF7 and SKOV3.ip1 cells were inoculated into an axillary mam-
mary fat pad of female FOX CHASE severe combined immunodeficient
(SCID) mice pretreated with 0.67 mg/ml estrone in drinking water for a week.
PC3-MDR cells were inoculated subcutaneously into the flank of male SCID
mice. Tumor diameters weremeasured using a caliper, and volumes were esti-
mated according to the formula: volume = 4/3 , p , r3. RIP1-Tag2 transgenic
mice (Hanahan, 1985) were treated as indicated from the age of 11 weeks. At
the age of 14weeks, the pancreaseswere dissected, andmacroscopic tumors
(>0.5 mm3) were counted and measured. Tumor volume was calculated by
using the formula for a spheroid: volume = 0.52 , (width)2 , length. RIP1-
Tag2 mice received 50% sugar food (Harlan) to relieve hypoglycemia induced
by the insulin-secreting tumors.
Transfections and Analyses of RNA and Proteins
Plasmids and siRNAs (20 nM) were transfected using Fugene HD transfection
reagent (Promega) and Oligofectamine or RNAi Max (Invitrogen) according to
the manufacturer’s instructions. pEF6-V5/His vector encoding for S508A
mutant of SMPD1 (SMPD1*), which has normal lysosomal activity but fails to
translocate to plasma membrane upon stress stimuli (Zeidan and Hannun,
2007), was kindly provided by Y. Hannun (University of South Carolina,
Charleston, SC, USA). Primer and siRNA sequences are listed in the Supple-
mental Experimental Procedures.ncer Cell 24, 379–393, September 9, 2013 ª2013 Elsevier Inc. 391
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ASM as a Target for Cancer TherapyFor the RNA sequencing (RNA-seq), total RNA was isolated from exponen-
tially growing cells using the Nucleospin RNA II kit (Macherey-Nagel). Single-
read 100 base pair libraries were constructed using the mRNA-Seq 8-Sample
Prep Kit (Illumina). Deep sequencing was performed at the National High-
Throughput DNA Sequencing Centre (University of Copenhagen, Copenha-
gen, Denmark) using Illumina Hiseq2000 instruments. Reads were aligned to
the mouse genomic sequence and quantified using the CLC genomic work-
bench software (CLC bio). Reads were mapped with a minimum of 50 bases
of consecutive matches allowing for up to three mismatches.
Protein separation and western blotting were performed using standard
procedures and antibodies listed in Supplemental Experimental Procedures.
Statistical Analyses
Statistical analysis was performed using a two-tailed, paired Student’s t test in
order to evaluate the null hypothesis. The cutoff level for statistical significance
was set to 5%, and all groups of data were tested for the comparability of their
variances using an F test.
ACCESSION NUMBERS
The GEO accession number for RNA-seq data is GSE46340.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found in this article online at http://
dx.doi.org/10.1016/j.ccr.2013.08.003.
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